Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Assembly Biosciences, Inc. before investing.

In this article, we go over a few key elements for understanding Assembly Biosciences, Inc.’s stock price such as:

• Assembly Biosciences, Inc.’s current stock price and volume
• Why Assembly Biosciences, Inc.’s stock price changed recently
• Upgrades and downgrades for ASMB from analysts
• ASMB’s stock price momentum as measured by its relative strength

About Assembly Biosciences, Inc. (ASMB)

Before we jump into Assembly Biosciences, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Want to learn more about Assembly Biosciences, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Assembly Biosciences, Inc..

Assembly Biosciences, Inc.’s Stock Price as of Market Close

As of April 17, 2026, 4:00 PM, CST, Assembly Biosciences, Inc.’s stock price was $29.240.

Assembly Biosciences, Inc. is down 0.27% from its previous closing price of $29.320.

During the last market session, Assembly Biosciences, Inc.’s stock traded between $28.790 and $30.190. Currently, there are approximately 16.94 million shares outstanding for Assembly Biosciences, Inc..

Assembly Biosciences, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Assembly Biosciences, Inc. Stock Price History

Assembly Biosciences, Inc.’s (ASMB) price is currently up 5.37% so far this month.

During the month of April, Assembly Biosciences, Inc.’s stock price has reached a high of $30.720 and a low of $28.050.

Over the last year, Assembly Biosciences, Inc. has hit prices as high as $39.705 and as low as $9.820. Year to date, Assembly Biosciences, Inc.’s stock is down 14.03%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Assembly Biosciences, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 17, 2026, there was 1 analyst who downgraded Assembly Biosciences, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Assembly Biosciences, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Assembly Biosciences, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Assembly Biosciences, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Assembly Biosciences, Inc. (ASMB) by visiting AAII Stock Evaluator.

Relative Price Strength of Assembly Biosciences, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 17, 2026, Assembly Biosciences, Inc. has a weighted four-quarter relative price strength of 18.93%, which translates to a Momentum Score of 89 and is considered to be Very Strong.

Want to learn more about how Assembly Biosciences, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Assembly Biosciences, Inc. Stock Price: Bottom Line

As of April 17, 2026, Assembly Biosciences, Inc.’s stock price is $29.240, which is down 0.27% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Assembly Biosciences, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.